Intravitreal injection of triamcinolone may improve vision in retinal vein occlusion

Image via Wikipedia

Medscape reported that, according to a study published in the Sept. issue of the Archives of Ophthalmology, intravitreal injection of the corticosteroid triamcinolone may improve vision in retinal vein occlusion.

Researchers from the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Research Group compared "the efficacy and safety of one-mg and four-mg doses of preservative-free intravitreal triamcinolone vs. observation for eyes with vision loss associated with macular edema secondary to perfused" central retinal vein occlusion "in 271 participants." They found that the the one-mg group had five-fold greater odds of achieving the primary outcome, as "did the four-mg group," with both the "one-mg and four-mg groups" being "not significantly different from each other."

Read more »

Lucentis met late-stage trial goal in patients with macular edema due to BRVO

Image via Wikipedia

Genentech, Inc. announced that its macular degeneration drug Lucentis [ranibizumab] met its goal in a late stage trial, improving the vision of patients with macular edema due to branch retinal vein occlusion.

Currently, Lucentis is approved to treat neurovascular, or 'wet,' age-related macular degeneration. Genentech is now trying to get the drug approved for macular edema due to branch retinal vein occlusion, a condition in which the macula, or central part of the retina, swells because fluid leaks or builds up.

Read more »